{"id":791404,"date":"2024-12-02T07:03:55","date_gmt":"2024-12-02T12:03:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/"},"modified":"2024-12-02T07:03:55","modified_gmt":"2024-12-02T12:03:55","slug":"tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/","title":{"rendered":"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy"},"content":{"rendered":"<h2>\nCompany to also provide an update on PLEXI-T\u2122 Phase 1 solid tumor trial<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">WALTHAM, Mass., Dec.  02, 2024  (GLOBE NEWSWIRE) &#8212; TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss data from the ALLOHA\u2122 Phase 1 heme trial presented at the ASH Annual Meeting and the clinical development strategy for the heme program. Additionally, the Company will provide an update on its PLEXI-T Phase 1 solid tumor trial. The virtual event will take place on Tuesday, December 10, at 8:00 a.m. ET.<\/p>\n<p align=\"justify\">The event will provide an in-depth review of the oral presentation describing the preliminary results from TScan\u2019s ongoing ALLOHA Phase 1 heme trial of TSC-100 and TSC-101 in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning. The Company will also provide updates with regards to a potential registrational path for the program following its initial meeting with the U.S. Food and Drug Administration (FDA), as well as future plans to expand the program.<\/p>\n<p align=\"justify\">Featured speakers include:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Ran Reshef, M.D., M.Sc., Director of Translational Research, Blood and Marrow Transplantation Program, Columbia University Irving Medical Center\n<\/li>\n<li style=\"text-align:justify\">Gavin MacBeath, Ph.D., Chief Executive Officer, TScan Therapeutics\n<\/li>\n<li style=\"text-align:justify\">Chrystal U. Louis, M.D., Chief Medical Officer, TScan Therapeutics\n<\/li>\n<li style=\"text-align:justify\">Shrikanta Chattopadhyay, M.D., Senior Vice President, Head of Translational Medicine, TScan Therapeutics<\/li>\n<\/ul>\n<p align=\"justify\">Registration for the live event can be found\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5Hb32N3fXI-T_gF9AyAVUm3xOSDZNcm9m44KDjqW2G-vO91R7Le_MaeQXrthAVJtOWX7eMmPnMEW3G00Nesq_6LUCLaU3715OHxIeWW_kmPFMKogGFJp7MxLe7RT7hpy\" rel=\"nofollow\" target=\"_blank\">here<\/a>. A replay will be made available on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nB0-035jLLQe80ZBNOUyI4K99C0BKsE2ONFp2X4gniKxpF9a7XkId0Fd7oFhimVzAt71QQJ3B5tCcZW2NRQTLTFOLX_hKva9apNkxi87rZKDMchF1SaOu4ucp_jvn3qZq1IBvJyGgMjG-Mn-GCCgYeWeAuONqeU04fgmIeqW6sPXRrxPoaLXbNrhT3g3rCp6hOrNqmdrQKUdiTpstYGAvtoiKieG3aRGVPUmslxIZ0bAzw2ro2ZAkMUx9pmzHN7ARYD86ws4zB3bFC7Vm7VEDJTO_30MIYXQvTGQTPAA73bD0Sbgztph6hWV52AlbZHfY7OGGCGU3aw1n3pZvUfGYA==\" rel=\"nofollow\" target=\"_blank\">Events and Presentations<\/a>\u201d section of the Company\u2019s investor relations website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4giQzFr7Uh2Rm4ozdnnuw2msGrI_WRlNYT18i4FBklnATIOaG1N0rCLOmfZzw-EDkqdY7TVudY869BR5HK9frXQQR3MoGzkTtbQdSMxEekcD-LasHo-jVmIRj3qAkQxG9mN-EUv3ApX0Y7Hh6QSmyoP6PMjzaZESzcoyfsd_UfE0X6QH4Tz3feQdlr9qt6_22dnn4Fl7py0FevhAK3VVZB7nvGkrvWSPaTWLA4xrt0E=\" rel=\"nofollow\" target=\"_blank\">ir.tscan.com<\/a>.<\/p>\n<p>\n        <strong>About TScan Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company\u2019s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA<sup>TM<\/sup>\u00a0Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company\u2019s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers and is enrolling patients into its ongoing PLEXI-T Phase 1 solid tumor trial.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>Heather Savelle<br \/>TScan Therapeutics, Inc.<br \/>VP, Investor Relations<br \/>857-399-9840<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lepC7BU05U30HLF5t6r6Zf2POrk5fL2cm1UrhSYc-ToE99CDbcpYJtRZJ0AiJVBPVgHKymP0ff_8ZCtq-W-esKISpjbmzzy34U2EDT1vHvE=\" rel=\"nofollow\" target=\"_blank\">hsavelle@tscan.com<\/a>\u00a0\u00a0\u00a0<\/p>\n<p>Maghan Meyers<br \/>Argot Partners<br \/>212-600-1902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Wp2_3LA3GUHeqOj-0KkfFMJFM9u5ZCdXe6uiiUuJGaAbrMGU5ZE8mt5SlT-PJho-cG4e69e45SSBs9IkKemR8jUZrIVzd1zdxdUE3Coh078=\" rel=\"nofollow\" target=\"_blank\">TScan@argotpartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDAyODRjYzYtYmUzYi00NjM3LWFlOTgtODYzNWY2ZWUxNDI3LTEyMTg2MjI=\/tiny\/TScan-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to also provide an update on PLEXI-T\u2122 Phase 1 solid tumor trial WALTHAM, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) &#8212; TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss data from the ALLOHA\u2122 Phase 1 heme trial presented at the ASH Annual Meeting and the clinical development strategy for the heme program. Additionally, the Company will provide an update on its PLEXI-T Phase 1 solid tumor trial. The virtual event will take place on Tuesday, December 10, at 8:00 a.m. ET. The event will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-791404","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to also provide an update on PLEXI-T\u2122 Phase 1 solid tumor trial WALTHAM, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) &#8212; TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss data from the ALLOHA\u2122 Phase 1 heme trial presented at the ASH Annual Meeting and the clinical development strategy for the heme program. Additionally, the Company will provide an update on its PLEXI-T Phase 1 solid tumor trial. The virtual event will take place on Tuesday, December 10, at 8:00 a.m. ET. The event will &hellip; Continue reading &quot;TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-02T12:03:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy\",\"datePublished\":\"2024-12-02T12:03:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/\"},\"wordCount\":445,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/\",\"name\":\"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk=\",\"datePublished\":\"2024-12-02T12:03:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/","og_locale":"en_US","og_type":"article","og_title":"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy - Market Newsdesk","og_description":"Company to also provide an update on PLEXI-T\u2122 Phase 1 solid tumor trial WALTHAM, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) &#8212; TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss data from the ALLOHA\u2122 Phase 1 heme trial presented at the ASH Annual Meeting and the clinical development strategy for the heme program. Additionally, the Company will provide an update on its PLEXI-T Phase 1 solid tumor trial. The virtual event will take place on Tuesday, December 10, at 8:00 a.m. ET. The event will &hellip; Continue reading \"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-02T12:03:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy","datePublished":"2024-12-02T12:03:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/"},"wordCount":445,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/","name":"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk=","datePublished":"2024-12-02T12:03:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjEyOCM2NjE3MTg2IzIyMDcwNjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-phase-1-trial-and-heme-development-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA\u2122 Phase 1 Trial and Heme Development Strategy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=791404"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791404\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=791404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=791404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=791404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}